Midazolam Base en es it fr

Midazolam Base Brand names, Midazolam Base Analogs

Midazolam Base Brand Names Mixture

  • No information avaliable

Midazolam Base Chemical_Formula


Midazolam Base RX_link


Midazolam Base fda sheet

Midazolam Base msds (material safety sheet)

Midazolam_Base MSDS

Midazolam Base Synthesis Reference

No information avaliable

Midazolam Base Molecular Weight

325.767 g/mol

Midazolam Base Melting Point

159 oC

Midazolam Base H2O Solubility

40.0 mg/ml

Midazolam Base State


Midazolam Base LogP


Midazolam Base Dosage Forms

Liquid; Solution

Midazolam Base Indication

For use in pediatric patients for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures or before induction of anesthesia.

Midazolam Base Pharmacology

Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.

Midazolam Base Absorption

Rapidly absorbed after oral administration (absolute bioavailability of the midazolam syrup in pediatric patients is about 36%, and intramuscular is greater than 90%).

Midazolam Base side effects and Toxicity

LD50=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.

Midazolam Base Patient Information

Midazolam Base Organisms Affected

Humans and other mammals